

Dansk Biokemi ApS.

Kystvej 26, 8500 Grenaa

CVR-nr./CVR no. 40 81 62 83

Årsrapport 2021

Annual report 2021

Godkendt på selskabets ordinære generalforsamling den 20. januar 2022

Approved at the Company's annual general meeting on 20 January 2022

Dirigent:

Chair of the meeting:

.....
Jørgen Lindhardt Steffensen

Dette dokument indeholder en oversættelse af den originale danske tekst. I tilfælde af uoverensstemmelse mellem den originale danske tekst og oversættelsen er den originale danske tekst gældende.

The English text is a translation of the original Danish text. The original Danish text is the governing text for all purposes, and in case of any discrepancy, the Danish wording will be applicable.

Indhold

Contents

Ledespåtegning	2
Statement by the Board of Directors and the Executive Board	
Den uafhængige revisors erklæring om opstilling af årsregnskab	4
Independent auditors' report on the compilation of financial statements	
Ledelsesberetning	5
Management's review	
Årsregnskab 1. januar - 31. december	10
Financial statements 1 January - 31 December	
Resultatopgørelse	10
Income statement	
Balance	11
Balance sheet	
Egenkapitalopgørelse	12
Statement of changes in equity	
Noter	13
Notes to the financial statements	

Ledelsespåtegning

Statement by the Board of Directors and the Executive Board

Bestyrelse og direktion har dags dato behandlet og godkendt årsrapporten for Dansk Biokemi ApS. for regnskabsåret 1. januar - 31. december 2021.

Årsrapporten, der ikke er revideret, er aflagt i overensstemmelse med årsregnskabsloven. Bestyrelse og direktion anser betingelserne for at undlade revision for opfyldt.

Det er vores opfattelse, at årsregnskabet giver et retvisende billede af selskabets aktiver, passiver og finansielle stilling pr. 31. december 2021 samt af resultatet af selskabets aktiviteter for regnskabsåret 1. januar - 31. december 2021.

Det er endvidere vores opfattelse, at ledelsesberetningen indeholder en retvisende redegørelse for de forhold, beretningen omhandler.

Det indstilles på generalforsamlingen, at årsregnskabet for 2022 ikke skal revideres.

Årsrapporten indstilles til generalforsamlingens godkendelse.

Grenaa, den 20. januar 2022

Grenaa, 20 January 2022

Direktion:/Executive Board:

.....
Svend Aage Brandstrup
Hansen
direktør/CEO

.....
Kristian Bennetsen
direktør/Executive Director

Bestyrelse/Board of Directors:

.....
Jørgen Lindhardt
Steffensen
formand/Chair

.....
Kristian Bennetsen

.....
Svend Aage Brandstrup
Hansen

.....
Otto Ulrich Michael
Andreae-Jäckering

Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Dansk Biokemi ApS. for the financial year 1 January - 31 December 2021.

The annual report, which has not been audited, has been prepared in accordance with the provisions of the Danish Financial Statements Act. The Board of Directors and the Executive Board have considered the criteria for omission of audit to be met.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2021 and of the results of the Company's operations for the financial year 1 January - 31 December 2021.

Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

It is proposed to the annual general meeting that the financial statements for 2022 should not be audited.

We recommend that the annual report be approved at the annual general meeting.

Generalforsamlingen har besluttet, at årsregnskabet for det kommende regnskabsår ikke skal revideres.

The general meeting has decided that the financial statements for the coming financial year will not be audited.

Den uafhængige revisors erklæring om opstilling af årsregnskab

Independent auditor's report on the compilation of financial statements

Til den daglige ledelse i Dansk Biokemi ApS.

Vi har opstillet årsregnskabet for Dansk Biokemi ApS. for regnskabsåret 1. januar - 31. december 2021 på grundlag af selskabets bogføring og øvrige oplysninger, som I har tilvejebragt.

Årsregnskabet omfatter resultatopgørelse, balance, egenkapitalopgørelse og noter, herunder anvendt regnskabspraksis.

Vi har udført opgaven i overensstemmelse med ISRS 4410 *Opgaver om opstilling af finansielle oplysninger*.

Vi har anvendt vores faglige ekspertise til at assistere jer med at udarbejde og præsentere årsregnskabet i overensstemmelse med årsregnskabsloven. Vi har overholdt relevante bestemmelser i revisorloven og International Ethics Standards Board for Accountants' internationale retningslinjer for revisoreres etiske adfærd (IESBA Code), herunder principper om integritet, objektivitet, professionel kompetence og fornøden omhu.

Årsregnskabet samt nøjagtigheden og fuldstændigheden af de oplysninger, der er anvendt til opstillingen af årsregnskabet, er jeres ansvar.

Da en opgave om opstilling af finansielle oplysninger ikke er en erklæringsopgave med sikkerhed, er vi ikke forpligtet til at verificere nøjagtigheden eller fuldstændigheden af de oplysninger, som I har givet os til brug for at opstille årsregnskabet. Vi udtrykker derfor ingen revisions- eller review-konklusion om, hvorvidt årsregnskabet er udarbejdet i overensstemmelse med årsregnskabsloven.

Aarhus, den 20. januar 2022

Aarhus, 20 January 2022

EY Godkendt Revisionspartnerselskab

CVR-nr. 30 70 02 28

Peter U. Faurischou

statsaut. revisor

State Authorised Public Accountant

mne34502

To the general management of Dansk Biokemi ApS.

We have compiled the financial statements of Dansk Biokemi ApS. for the financial year 1 January - 31 December 2021 based on the Company's bookkeeping and other information provided.

The financial statements comprise an income statement, balance sheet, statement of changes in equity and notes, including accounting policies.

We performed this compilation engagement in accordance with ISRS 4410 *Compilation Engagements*.

We have applied our expertise in accounting and financial reporting to assist you in the preparation and presentation of the financial statements in accordance with the Danish Financial Statements Act. We have complied with relevant requirements in the Danish Auditors Act and International Ethics Standards Board for Professional Accountants' International Code of Ethics for Professional Accountants (IESBA Code), including principles of integrity, objectivity, professional competence and due care.

The financial statements and the accuracy and completeness of the information used to compile the financial statements are your responsibility.

Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile the financial statements. Accordingly, we do not express an audit opinion or a review conclusion on whether the financial statements are prepared in accordance with the Danish Financial Statements Act.

Ledelsesberetning

Management's review

Oplysninger om selskabet

Company details

Navn/Name	Dansk Biokemi ApS.
Adresse, postnr., by/Address, Postal code, City	Kystvej 26, 8500 Grenaa
CVR-nr./CVR no.	40 81 62 83
Stiftet/Established	24. september 2019/24 September 2019
Hjemstedskommune/Registered office	Norrdjurs
Regnskabsår/Financial year	1. januar - 31. december/1 January - 31 December
Bestyrelse/Board of Directors	Jørgen Lindhardt Steffensen, formand/Chair Kristian Bennetsen Svend Aage Brandstrup Hansen Otto Ulrich Michael Andreae-Jäckering
Direktion/Executive Board	Svend Aage Brandstrup Hansen, direktør/CEO Kristian Bennetsen, direktør/Executive Director
Revisor/Accountant	EY Godkendt Revisionspartnerselskab Værkmestergade 25, Postboks 330, 8100 Aarhus C

Ledelsesberetning

Management's review

Virksomhedens væsentligste aktiviteter

Selskabets formål

At etablere det første PLA-produktionsanlæg i Nordeuropa. En bio-polymer til videresalg til producenter af bioplastapplikationer. Den første del af processen (Fase 1) bliver et hvede-bioraffinaderi til fraktionering af protein- og fiberprodukter, samt omdannelse af hvedens indhold af stivelse til glukose. Fase 2 er processering af glukose til PLA biopolymer.

Primære aktiviteter

At tilvejebringe den nødvendige knowhow via samarbejde med teknologi- og ingeniørselskaber som har ekspertise, og licenser indenfor fraktionering af hvedekorn, foruden omdannelse af stivelse til glukose og produktion af PLA Biopolymer. Selskabets anden prioritering består i at tilvejebringe den nødvendige ejerkapital og ansvarlige lånekapital, foruden den nødvendige lånefinansiering til total finansiering af produktionsanlægget.

Sekundær aktivitet

Dansk Biokemi ApS. har i 2021 solgt gluten protein og stivelse i Danmark på kommission fra Jäckering Gruppe.

Udvikling i aktiviteter og økonomiske forhold

Virksomhedens resultatopgørelse for 2021 udviser et underskud på 15 t.kr. mod et overskud på 8 t.kr. sidste år, og virksomhedens balance pr. 31. december 2021 udviser en egenkapital på 53 t.kr.

Årets resultat anses som tilfredsstillende. Selskabets stiftelseskapital er intakt efter den opnåede kommission af salg af gluten og stivelse. Selskabets bestyrelse har jævnlige holdt møder, og i fællesskab tilrettelagt alle aktiviteter.

Business review

The purpose of the company

To establish the first PLA production facility in Northern Europe. A biopolymer for resale to manufacturers of bioplastic applications. The first part of the process (Phase 1) will be a wheat biorefinery for the fractionation of protein and fibre products, as well as the conversion of the wheat starch into glucose. Phase 2 is the processing of glucose into PLA biopolymer.

Primary activities

To provide the necessary know-how through collaboration with technology and engineering companies that have the expertise and licenses within the fractionation of wheat grains, in addition to the conversion of starch to glucose and to produce PLA Biopolymer. The second priority of DB is to secure the necessary equity and subordinated loan capital, in addition to the required equity- and debt funding for financing the total production plant.

Secondary activity

Dansk Biokemi ApS. has sold gluten protein and starch in Denmark in 2021 on commission from the Jäckering Group.

Financial review

The income statement for 2021 shows a loss of DKK 15 thousand against a profit of DKK 8 thousand last year, and the balance sheet at 31 December 2021 shows equity of DKK 53 thousand.

The result for the year is considered satisfactory. The company's founding capital is intact following the commission obtained from the sale of gluten and starch. The company's board of directors has held regular meetings and jointly organized all activities.

Ledelsesberetning

Management's review

Med basis i det tekniske forarbejde og den ekspertise Dansk Biokemi ApS. har oparbejdet, er der tilrettelagt et aktivitets- og budgetforløb som inkluderer etablering af projektledelse, udarbejdelse af projektgennemførelsesmanual, med opdeling af kontraktleveringsaftaler, og der er lokaliseret leverandører. Foruden at der søges nødvendige miljø- og byggetilladelser til projektets gennemførelse. Opstart af aktivitets- og budgetforløb er sat til januar 2022 og løber til medio 2023.

Der er lavet benchmark af produktionsprocessen og råvareforsyningen i henhold til certificeringsregler i Danmark og Tyskland, samt EU's generelle regler.

Det økonomiske fundament (forretningsplanen) er yderligere gennemgået (dec. 2021) og detaljeret kvalitetssikret, bl.a. via benchmark af priser på alle sideprodukter fra hvede-bioraffinaderiet, og kendskab til priser på PLA biopolymer på det europæiske marked.

En afgørende faktor i Dansk Biokemi ApS.'s forretningsplan er placeringen ved Nakskov Havn. Omkostninger til transport af råvarer og færdigprodukter vil være klart reduceret i forhold til andre EU baserede produktionsanlæg.

Dansk Biokemi ApS. har identificeret nye afsætningsmuligheder for det flydende restfoderprodukt. Der er lavet foderanalyser og testforsøg på alternative anvendelsesmuligheder og Dansk Biokemi ApS. har flere alternativer i spil.

Hvede bioraffinaderi

Ejerkredsen af Dansk Biokemi ApS. blev i 2021 udvidet og Jäckering Mühlen- und Nährmittelwerke GmbH ("Jäckering Gruppe") indtrådte som anpartshaver. Jäckering Gruppe bliver ansvarlig for videns overførslen i forbindelse med opførelsen af hvede-bioraffinaderiet, der grundlæggende bliver et replika af Jäckering's (2021) nye fabriksanlæg i Tyskland.

Glukose produktion af hvedestivelse

Dansk Biokemi ApS. har samarbejdet i 3 år med et dansk ingeniørselskab som har alle kompetencer og referencer på processen hvor stivelse omdannes til glukose (DE95).

Based on the technical preparation and the expertise Dansk Biokemi ApS. has gained, an activity plan and budgeted process have been organized which includes the establishment of the project management, preparation of the project implementation manual, including contract delivery agreements with 3rd parties, and the technical suppliers have been located. In addition to applying for the required environmental- and building permits for the realisation of the project. The activities and budget processes is planned to commence in January 2022 and runs until mid-2023.

Benchmark comparisons have been made of the production process and raw material supply in accordance with certification rules in Denmark and Germany, as well as the EU's general rules.

The financial foundation (business plan) has been further reviewed (Dec. 2021) and detailed quality assured, i.e., via benchmark of prices of all by-products from the wheat refinery, and knowledge of PLA biopolymer prices in the European market.

A crucial factor in Dansk Biokemi ApS.'s business plan is the location at the Port of Nakskov Harbour. The cost for sourcing raw materials (wheat transport) and shipment of final products will be reduced and the location is competitive compared to other EU-based production sites.

Dansk Biokemi ApS. has identified new outlets for its liquid by-products. The by-products have been analysed, plus selective trials have been conducted on alternative usage and applications of this side stream. The final applicability of the by-products have not been chosen.

Wheat biorefinery

The ownership of Dansk Biokemi ApS. was enlarged in 2021 and Jäckering Mühlen- und Nährmittelwerke GmbH ("Jäckering Group") became a shareholder. The Jäckering Group will be responsible for the transfer of knowledge in connection with the construction of the wheat biorefinery, which will basically be a replica of Jäckering's (2021) new plant in Germany.

Glucose production of wheat starch

Dansk Biokemi ApS. has for more than 3 years collaborated with a Danish engineering company which has all the competencies and references within the process of converting starch to glucose (DE95).

Ledelsesberetning

Management's review

Biopolymer PLA fra glukose

Dansk Biokemi ApS. har forberedt et Feasibility studie med et udenlandsk ingeniørteam, der har specialiseret sig i etablering af PLA-produktionsanlæg baseret på forskellige typer af glukose. Studiet er en del af arbejdet i Projektselskabet.

PLA Biopolymer til videre produktion af Bioplastapplikationer

Bioplastproducenter i Europa efterspørger PLA Biopolymer til deres produktion af forskellige typer af bioplastapplikationer.

Bioplastapplikationerne rækker fra almindelige bionedbrydelige plastikposer, over bestik og service til husholdning, til faste bioplastikprodukter til brug indenfor automobilindustrien eller biofibre til tøjproduktion.

Produktion af PLA Biopolymer er i dag placeret i Thailand og Kina foruden i Arkansas i USA. Dvs. alle europæiske bioplastproducenter importerer deres Biopolymer til et underforsynet marked, hvor efterspørgslen er betydelig større end udbuddet. Dansk Biokemi ApS. har via netværk og kontakt til bioplastproducenter opsamlet denne viden. I 2022 vil Dansk Biokemi ApS. foretage yderligere undersøgelse og kortlægning af markedet.

Lokation

Dansk Biokemi ApS. vil placere produktionsanlægget ved Nakskov Havn. Placering af valgt pga. den lokale hvedeproduktion på Lolland-Falster og Syd-sjælland, adgangen til vedværende energikilder og procesvand, samt adgangen til Nakskov Havn for råvarelevering og afsætning af færdigvarer via skib.

Producing biopolymer from glucose

Dansk Biokemi ApS. has prepared a Feasibility study with a foreign engineering team specializing in the establishment of PLA production facilities based on different types of glucose. The study is part of the initial project work at the Project Company.

PLA Biopolymer for further production of Bioplastic applications

Bioplastics manufacturers in Europe demand PLA Biopolymer for their production of different types of bioplastics applications. The bioplastic applications range from ordinary biodegradable plastic bags, cutlery and tableware for the household, to solid bioplastic products for use in for instance the automotive industry or as biofibres to within the clothing industry.

The global production of PLA Biopolymer is currently located in Thailand and China as well as in Arkansas in the USA. Therefore, the European bioplastic producers are importing their biopolymers into a market where demand far exceed the supply. Dansk Biokemi ApS. has gained this industry insight via its network and contact with bioplastic producers. Dansk Biokemi ApS. will undertake further research and mapping of the PLA market during the project work in 2022.

Location

Dansk Biokemi ApS. will locate its production plant at Nakskov Harbor. The Location is chosen due to the local/regional wheat production on Lolland-Falster and at the Southern part of Zealand, access to local renewable energy sources and process water, as well as access to Nakskov Harbour is crucial for the sourcing of further raw materials and shipping of the final goods.

Ledelsesberetning

Management's review

Finansiering

Finansieringsarbejdet er opdelt i 2 steps:

1) Den indledende finansiering af Projektselskabet som inkluderer indledende Feasibility studier, basis ingeniørberegninger, aftaler med leverandører indenfor forsyning, energi, vand o. lign. Denne finansiering indeholder også at der udarbejdes ansøgninger til Miljøtilladelse og VVM-godkendelse. Der er afsat en tidshorizont til færdiggørelse af dette arbejde fra januar 2022 til medio 2023.

2) Finansiering af både den nødvendige ejerkapital og lånefinansiering hvor udgangspunktet bliver de resultater der opnås fra arbejdet i Projektselskabet, og formuleres i en detaljeret forretningsplan.

Begivenheder efter balancedagen

Der er ikke efter balancedagen indtruffet begivenheder af væsentlig betydning for virksomhedens finansielle stilling.

Financing

The funding of activities is divided into 2 steps:

1) The initial funding of the Project Company which includes initial Feasibility studies, basic engineering calculations, agreements with utility suppliers (certified). The funding also includes the preparation and approvals of the applications for the environmental- and construction permits. A time horizon to complete this step has been planned from January 2022 until mid-2023.

2) Securing the funding for the required equity and debt funding for the construction of the production plant, the details of this will be completed as a part of the project work until mid- 2023.

Events after the balance sheet date

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.

Årsregnskab 1. januar - 31. december

Financial statements 1 January - 31 December

Resultatopgørelse

Income statement

Note	DKK	2021 12 mdr. (months)	2019/20 16 mdr. (months)
	Bruttofortjeneste/bruttotab Gross profit/loss	-16.647	11.686
	Finansielle omkostninger Financial expenses	-1.650	-227
	Resultat før skat Profit/loss before tax	-18.297	11.459
3	Skat af årets resultat Tax for the year	3.589	-3.762
	Årets resultat Profit/loss for the year	<u>-14.708</u>	<u>7.697</u>
	Forslag til resultatdisponering Recommended appropriation of profit/loss		
	Overført resultat Retained earnings/accumulated loss	<u>-14.708</u>	<u>7.697</u>
		<u>-14.708</u>	<u>7.697</u>

Årsregnskab 1. januar - 31. december

Financial statements 1 January - 31 December

Balance

Balance sheet

Note	DKK	2021	2019/20
Note			
	AKTIVER		
	ASSETS		
	Omsætningsaktiver		
	Non-fixed assets		
	Tilgodehavender		
	Receivables		
	Tilgodehavende sambeskatningsbidrag	5.745	0
	Joint taxation contribution receivable		
	Andre tilgodehavender	6.143	2.832
	Other receivables		
		<u>11.888</u>	<u>2.832</u>
	Likvide beholdninger	<u>60.067</u>	<u>58.627</u>
	Cash		
	Omsætningsaktiver i alt	<u>71.955</u>	<u>61.459</u>
	Total non-fixed assets		
	AKTIVER I ALT	<u>71.955</u>	<u>61.459</u>
	TOTAL ASSETS		
	PASSIVER		
	EQUITY AND LIABILITIES		
	Egenkapital		
	Equity		
	Selskabskapital	60.000	40.000
	Share capital		
	Overført resultat	-7.011	7.697
	Retained earnings		
	Egenkapital i alt	<u>52.989</u>	<u>47.697</u>
	Total equity		
	Gældsforpligtelser		
	Liabilities other than provisions		
	Kortfristede gældsforpligtelser		
	Current liabilities other than provisions		
	Leverandører af varer og tjenesteydelser	12.119	10.000
	Trade payables		
	Skyldig selskabsskat	2.156	3.762
	Corporation tax payable		
	Gæld til selskabsdeltagere og ledelse	3.762	0
	Payables to shareholders and management		
	Anden gæld	929	0
	Other payables		
		<u>18.966</u>	<u>13.762</u>
	Gældsforpligtelser i alt	<u>18.966</u>	<u>13.762</u>
	Total liabilities other than provisions		
	PASSIVER I ALT	<u>71.955</u>	<u>61.459</u>
	TOTAL EQUITY AND LIABILITIES		

- 1 Anvendt regnskabspraksis
Accounting policies
- 2 Personalemkostninger
Staff costs
- 4 Kontraktlige forpligtelser og eventualposter m.v.
Contractual obligations and contingencies, etc.
- 5 Sikkerhedsstillelser
Collateral

Årsregnskab 1. januar - 31. december

Financial statements 1 January - 31 December

Egenkapitaloppgørelse

Statement of changes in equity

DKK	Selskabskapital Share capital	Overført resultat Retained earnings	I alt Total
Egenkapital 1. januar 2021 Equity at 1 January 2021	40.000	7.697	47.697
Kapitalforhøjelse Capital increase	20.000	0	20.000
Overført via resultatdisponering Transfer through appropriation of loss	0	-14.708	-14.708
Egenkapital 31. december 2021 Equity at 31 December 2021	<u>60.000</u>	<u>-7.011</u>	<u>52.989</u>

Årsregnskab 1. januar - 31. december

Financial statements 1 January - 31 December

Noter

Notes to the financial statements

1 Anvendt regnskabspraksis

Accounting policies

Årsrapporten for Dansk Biokemi ApS. for 2021 er aflagt i overensstemmelse med årsregnskabslovens bestemmelser for klasse B-virksomheder med tilvalg af visse bestemmelser for klasse C.

Virksomheden har med virkning for regnskabsåret 2021 implementeret ændringslov nr. 1716 af 27. december 2018 til årsregnskabsloven. Implementeringen af ændringsloven har ikke påvirket virksomhedens regnskabspraksis for indregning og måling af aktiver og forpligtelser, men har alene betydet krav om yderligere oplysninger. Årsregnskabet er aflagt efter samme regnskabspraksis som sidste år.

Præsentationsvaluta

Årsregnskabet er aflagt i danske kroner (DKK).

Resultatopgørelsen

Bruttofortjeneste/bruttotab

I resultatopgørelsen er nettoomsætning, andre driftsindtægter og eksterne omkostninger med henvisning til årsregnskabslovens § 32 sammen draget til én regnskabspost benævnt bruttofortjeneste/bruttotab.

Andre driftsindtægter

Andre driftsindtægter indeholder regnskabsposter af sekundær karakter i forhold til virksomhedens hovedaktiviteter.

Eksterne omkostninger

Andre eksterne omkostninger omfatter omkostninger vedrørende virksomhedens primære aktivitet, der er afholdt i årets løb, herunder omkostninger til administration mv.

Finansielle omkostninger

Finansielle omkostninger indregnes i resultatopgørelsen med de beløb, der vedrører regnskabsåret. Finansielle poster omfatter renteomkostninger samt valutakursdifference.

The annual report of Dansk Biokemi ApS. for 2021 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Effective from the financial year 2021, the Company has implemented amending act no. 1716 of 27 December 2018 to the Danish Financial Statements Act. The implementation of the amending act has not affected the Company's accounting policies on recognition and measurement of assets and liabilities but has solely entailed a requirement for further disclosures. The accounting policies used in the preparation of the financial statements are consistent with those of last year.

Reporting currency

The financial statements are presented in Danish kroner (DKK).

Income statement

Gross profit/loss

The items revenue, other operating income and external expenses have been aggregated into one item in the income statement called gross profit/loss in accordance with section 32 of the Danish Financial Statements Act.

Other operating income

Other operating income comprise items of a secondary nature relative to the Company's core activities.

External expenses

Other external expenses include the year's expenses relating to the Company's core activities, including expenses relating to administration etc.

Financial expenses

Financial expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest expenses as well as exchange rate difference.

Årsregnskab 1. januar - 31. december

Financial statements 1 January - 31 December

Noter

Notes to the financial statements

1 Anvendt regnskabspraksis (fortsat)

Accounting policies (continued)

Skat

Skat af årets resultat omfatter aktuel skat af årets forventede skattepligtige indkomst og årets regulering af udskudt skat. Årets skat indregnes i resultatopgørelsen med den del, der kan henføres til årets resultat, og i egenkapitalen med den del, som kan henføres til transaktioner indregnet i egenkapitalen.

Virksomheden indgår i sambeskatning med øvrige koncernvirksomheder. Den danske selskabsskat fordeles mellem overskuds- og underskudsgivende danske selskaber i forhold til disse skattepligtige indkomst (fuld fordeling).

Sambeskattede selskaber med overskydende skat godtgøres som minimum i henhold til de gældende satser for rentegodtgørelser af administrationselskabet, ligesom sambeskattede selskaber med restskat som maksimum betaler et tillæg i henhold til de gældende satser for rentetillæg til administrationselskabet.

Balancen

Tilgodehavender

Tilgodehavender måles til amortiseret kostpris.

Der foretages nedskrivning til imødegåelse af tab, hvor der vurderes at være indtruffet en objektiv indikation på, at et tilgodehavende eller en portefølje af tilgodehavender er værdiforringet. Hvis der foreligger en objektiv indikation på, at et individuelt tilgodehavende er værdiforringet, foretages nedskrivning på individuelt niveau.

Likvider

Likvider omfatter likvide beholdninger og kortfristede værdipapirer, som uden hindring kan omsættes til likvide beholdninger, og hvorpå der kun er ubetydelige risici for værdiændringer.

Selskabsskat

Aktuelle skatteforpligtelser indregnes i balancen som beregnet skat af årets skattepligtige indkomst, reguleret for skat af tidligere års skattepligtige indkomster samt betalte acontoskatter.

Tax

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

The entity is jointly taxed with other group entities. The total Danish income tax charge is allocated between profit/loss-making Danish entities in proportion to their taxable income (full absorption).

Jointly taxed entities entitled to a tax refund are reimbursed by the management company based on the rates applicable to interest allowances, and jointly taxed entities which have paid too little tax pay a surcharge according to the rates applicable to interest surcharges to the management company.

Balance sheet

Receivables

Receivables are measured at amortised cost.

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.

Cash

Cash comprise cash and short term securities which are readily convertible into cash and subject only to minor risks of changes in value.

Income taxes

Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.

Årsregnskab 1. januar - 31. december

Financial statements 1 January - 31 December

Noter

Notes to the financial statements

1 Anvendt regnskabspraksis (fortsat)

Accounting policies (continued)

Udskudt skat måles efter den balanceorienterede gælds metode af alle midlertidige forskelle mellem regnskabsmæssig og skattemæssig værdi af aktiver og forpligtelser. Der indregnes dog ikke udskudt skat af midlertidige forskelle vedrørende skattemæssigt ikke-afskrivningsberettiget goodwill og kontorejendomme samt andre poster, hvor midlertidige forskelle bortset fra virksomhedsovertagelser er opstået på anskaffelsestidspunktet uden at have indvirkning på resultat eller skattepligtig indkomst. I de tilfælde, hvor opgørelse af skatteværdien kan foretages efter forskellige beskatningsregler, måles udskudt skat på grundlag af den af ledelsen planlagte anvendelse af aktivet, henholdsvis afvikling af forpligtelsen.

Udskudt skat måles på grundlag af de skatteregler og skattesatser, der med balancedagens lovgivning vil være gældende, når den udskudte skat forventes udløst som aktuel skat. Udskudte skatteaktiver indregnes med den værdi, som de forventes at blive udnyttet med, enten ved udligning i skat af fremtidig indtjening eller ved modregning i udskudte skatteforpligtelser inden for samme jurisdiktion. Ændring i udskudt skat som følge af ændringer i skattesatser indregnes i resultatopgørelsen.

Gældsforpligtelser

Finansielle gældsforpligtelser indregnes ved lånoptagelse til det modtagne provenu efter fradrag af afholdte transaktionsomkostninger. I efterfølgende perioder måles de finansielle forpligtelser til amortiseret kostpris, svarende til den kapitaliserede værdi ved anvendelse af den effektive rente, så forskellen mellem provenuet og den nominelle værdi indregnes i resultatopgørelsen over låneperioden. I finansielle forpligtelser indregnes tillige den kapitaliserede restleasingforpligtelse på finansielle leasingkontrakter.

Øvrige gældsforpligtelser måles til nettorealiseringsværdien.

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items where temporary differences, apart from business combinations, arise at the date of acquisition without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on Management's intended use of the asset or settlement of the liability, respectively.

Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement.

Liabilities

Financial liabilities are recognised at the date of borrowing at the net proceeds received less transaction costs paid. On subsequent recognition, financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest rate. Accordingly, the difference between the proceeds and the nominal value is recognised in the income statement over the term of the loan. Financial liabilities also include the capitalised residual lease liability in respect of finance leases.

Other liabilities are measured at net realisable value.

Årsregnskab 1. januar - 31. december

Financial statements 1 January - 31 December

Noter

Notes to the financial statements

2 Personalemkostninger
Staff costs

Virksomheden har ingen ansatte.

The Company has no employees.

DKK	2021 12 mdr. (months)	2019/20 16 mdr. (months)
3 Skat af årets resultat		
Tax for the year		
Beregnet skat af årets skattepligtige indkomst	2.156	3.762
Estimated tax charge for the year		
Refusion i sambeskatning	-5.745	0
Refund in joint taxation		
	<u>-3.589</u>	<u>3.762</u>

4 Kontraktlige forpligtelser og eventualposter m.v.
Contractual obligations and contingencies, etc.**Andre eventualforpligtelser**

Other contingent liabilities

Virksomheden er sambeskattet med modervirksomheden BRANDSTRUP/COLE HOLDING ApS som administrationselskab frem til og med 15. juni 2021 og hæfter begrænset og subsidiært med øvrige sambeskattede selskaber for betaling af selskabsskat samt for kildeskat på renter, royalties og udbytter.

The Company is jointly taxed until 15 June 2021 with its former parent company, BRANDSTRUP/COLE HOLDING ApS, which acts as management company, and has limited and alternative liability together with other jointly taxed group entities for payment of income taxes as well as withholding taxes on interest, royalties and dividends.

5 Sikkerhedsstillelser
Collateral

Virksomheden har ikke stillet pant eller anden sikkerhed i aktiver pr. 31. december 2021.

The Company has not provided any security or other collateral in assets at 31 December 2021.

Penneo

The signatures in this document are legally binding. The document is signed using Penneo™ secure digital signature. The identity of the signers has been recorded, and are listed below.

"By my signature I confirm all dates and content in this document."

Svend Aage Brandstrup Hansen

CEO

On behalf of: Dansk Biokemi ApS.

Serial number: PID:9208-2002-2-767846224045

IP: 130.185.xxx.xxx

2022-01-21 11:44:14 UTC

NEM ID 

Kristian Bennetsen

Executive Director

On behalf of: Dansk Biokemi ApS.

Serial number: PID:9208-2002-2-006048865089

IP: 93.178.xxx.xxx

2022-01-21 12:51:04 UTC

NEM ID 

Kristian Bennetsen

Board of Directors

On behalf of: Dansk Biokemi ApS.

Serial number: PID:9208-2002-2-006048865089

IP: 93.178.xxx.xxx

2022-01-21 12:52:08 UTC

NEM ID 

Svend Aage Brandstrup Hansen

Board of Directors

On behalf of: Dansk Biokemi ApS.

Serial number: PID:9208-2002-2-767846224045

IP: 80.208.xxx.xxx

2022-01-23 13:55:25 UTC

NEM ID 

Jørgen Lindhardt Steffensen

Chairman

On behalf of: Dansk Biokemi ApS.

Serial number: PID:9208-2002-2-943525658866

IP: 91.215.xxx.xxx

2022-01-24 11:01:46 UTC

NEM ID 

Jørgen Lindhardt Steffensen

Chair

On behalf of: Dansk Biokemi ApS.

Serial number: PID:9208-2002-2-943525658866

IP: 91.215.xxx.xxx

2022-01-24 11:01:46 UTC

NEM ID 

Otto Ulrich Michael Andreae-Jäkering

Board of Directors

On behalf of: Dansk Biokemi ApS.

Serial number: m.andreae@jaeckering.de

IP: 78.94.xxx.xxx

2022-01-24 12:44:51 UTC



Peter Ulrik Faurshou

State Authorised Public Accountant

On behalf of: EY Godkendt Revisionspartnerselskab

Serial number: CVR:30700228-RID:78371490

IP: 145.62.xxx.xxx

2022-01-24 14:42:07 UTC

NEM ID 

This document is digitally signed using Penneo.com. The digital signature data within the document is secured and validated by the computed hash value of the original document. The document is locked and timestamped with a certificate from a trusted third party. All cryptographic evidence is embedded within this PDF, for future validation if necessary.

How to verify the originality of this document

This document is protected by an Adobe CDS certificate. When you open the

document in Adobe Reader, you should see, that the document is certified by **Penneo e-signature service** <penneo@penneo.com>. This guarantees that the contents of the document have not been changed.

You can verify the cryptographic evidence within this document using the Penneo validator, which can be found at <https://penneo.com/validate>